Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Raises Price Target to $88
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jeff Jones maintains an Outperform rating on Corbus Pharmaceuticals (NASDAQ:CRBP) and raises the price target from $80 to $88.
August 07, 2024 | 11:57 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer analyst Jeff Jones maintains an Outperform rating on Corbus Pharmaceuticals and raises the price target from $80 to $88.
The raised price target and maintained Outperform rating from a reputable analyst at Oppenheimer is likely to positively impact investor sentiment and drive short-term price appreciation for Corbus Pharmaceuticals.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100